



Market Announcement

16 December 2019

Antisense Therapeutics Limited (ASX: ANP) – Suspension from Official Quotation

Description

The securities of Antisense Therapeutics Limited ('ANP') will be suspended from quotation immediately under Listing Rule 17.2, at the request of ANP, pending the release of an announcement regarding clinical trial results.

Issued by

Cheng Tang

Senior Adviser, Listings Compliance (Melbourne)

Monday 16 December 2019

Cheng Tang
Principal Adviser
Listings Compliance (Melbourne)
ASX Compliance Pty Limited

Email: Cheng.tang@asx.com.au

Dear Cheng,

Request for Suspension for Antisense Therapeutics Limited

In accordance with ASX Listing Rule 17.2, the Company requests an immediate Suspension in respect of its securities (ASX Code: ANP), pending release of an announcement in relation to the Company's ATL1102 for DMD Phase II clinical trial.

In requesting the Suspension, the Company provides the following information:

- The Suspension is requested in respect of finalising of an announcement following the Company's reporting of results following the completion of dosing in all patients in the Company's ATL1102 for DMD Phase II clinical trial;
- Unless otherwise requested by the Company, ANP requests the Suspension to remain in place until the release of an announcement expected on the morning of Tuesday 17 December 2019; and
- The Company is not aware of any reason why the Suspension should not be granted or of any other information necessary to inform the market about the Suspension.

Yours sincerely,



Phillip Hains
Company Secretary

The Board authorise the request by the Company Secretary for this Suspension.